Please assess the completion status of the following clinical trial:

Trial Title: Study of Vintafolide (MK-8109, EC145) in Participants With Advanced Ovarian and Endometrial Cancers (MK-8109-007, EC-FV-02)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Part A:~Inclusion Criteria:~* Radiographic evidence of measurable disease (by Response Evaluation Criteria In Solid Tumors \[RECIST\]) and either:~  * Advanced epithelial ovarian cancer with serous or endometrioid histology, as confirmed by previous biopsy or,~ * ertafolide scan positive ovarian cancer, primary peritoneal cancer or adenocarcinoma of the endometrium.~* Prior treatment with platinum and/or taxane compounds.~* Eastern Cooperative Oncology Group (ECOG) Performance status of 0-2.~* At least 4 weeks from prior therapy and recovered from associated acute toxicities.~* Adequate bone marrow reserve, renal, and hepatic function.~* Negative serum pregnancy test for women of childbearing potential and willingness to practice contraceptive methods.~Exclusion Criteria:~* Serious comorbidities (as determined by the Principal Investigator).~* Women who are pregnant or lactating.~* Symptomatic central nervous system (CNS) metastasis.~* Prior radiation therapy to assessable disease, unless disease progression is confirmed at that site.~* Requires palliative radiotherapy at time of study entry.~* Unable to tolerate conditions for radionuclide imaging.~* Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational.~* Those who have been administered another radiopharmaceutical that would interfere with the assessment of 99mTc-ertafolide scan.~Part B:~Inclusion Criteria:~* Radiographic evidence of measurable disease (by RECIST criteria)~* ertafolide scan positive recurrent or persistent epithelial ovarian, primary fallopian tube, or peritoneal cancer.~* Prior treatment with platinum compounds, but not more than 4 prior cytotoxic chemotheraputic regimens.~* ECOG Performance status of 0-2.~* At least 3 weeks from prior cytotoxic therapy and recovered from associated acute toxicities.~* Adequate bone marrow reserve, renal, and hepatic function.~* Negative serum pregnancy test for women of childbearing potential and willingness to practice contraceptive methods.~Exclusion Criteria:~* Serious comorbidities (as determined by the Principal Investigator).~* Women who are pregnant or lactating.~* Symptomatic CNS metastasis.~* Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational.~* Those who have had prior therapy with Vinorelbine or vinca-containing compounds.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ertafolide + Vintafolide (Type: EXPERIMENTAL): Screening: After completion of all screening procedures and confirmation of eligibility, all participants receive a 1- to 2-mL injection of 0.1 mg ertafolide labeled with 20 to 25 mCi of technetium-99m Part A: Induction phase of treatment: Two 4-week cycles; if stable disease or better at week 8 computed tomography (CT), participant may proceed into maintenance phase, comprised of 4-week cycles with CT every 8 weeks. Participants continue on study until they experience disease progression, unacceptable toxicity, or attain protocol-defined clinical benefit. Part B: 4-week cycles with CT every 8 weeks. Participants continue until they experience disease progression, unacceptable toxicity, or attain protocol-defined clinical benefit.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete